Integrin alphavbeta5 regulates lung vascular permeability and pulmonary endothelial barrier function.
Increased lung vascular permeability is an important contributor to respiratory failure in acute lung injury (ALI). We found that a function-blocking antibody against the integrin alphavbeta5 prevented development of lung vascular permeability in two different models of ALI: ischemia-reperfusion in rats (mediated by vascular endothelial growth factor [VEGF]) and ventilation-induced lung injury (VILI) in mice (mediated, at least in part, by transforming growth factor-beta [TGF-beta]). Knockout mice homozygous for a null mutation of the integrin beta5 subunit were also protected from lung vascular permeability in VILI. In pulmonary endothelial cells, both the genetic absence and blocking of alphavbeta5 prevented increases in monolayer permeability induced by VEGF, TGF-beta, and thrombin. Furthermore, actin stress fiber formation induced by each of these agonists was attenuated by blocking alphavbeta5, suggesting that alphavbeta5 regulates induced pulmonary endothelial permeability by facilitating interactions with the actin cytoskeleton. These results identify integrin alphavbeta5 as a central regulator of increased pulmonary vascular permeability and a potentially attractive therapeutic target in ALI.
Su
George
G
Lung Biology Center, Division of Pulmonary and Critical Care Medicine, Laboratory of Surgical Research, Department of Anesthesia, and Cardiovascular Research Institute, University of California, San Francisco, California 94158, USA.
Hodnett
Maki
M
Wu
Nanyan
N
Atakilit
Amha
A
Kosinski
Cynthia
C
Godzich
Mika
M
Huang
Xiao Zhu
XZ
Kim
Jiyeun K
JK
Frank
James A
JA
Matthay
Michael A
MA
Sheppard
Dean
D
Pittet
Jean-François
JF
D000577:Amides / Q000494:pharmacology; D000818:Animals; D000906:Antibodies / Q000276:immunology; D015824:Blood-Air Barrier / Q000187:drug effects / Q000378:metabolism*; D002199:Capillary Permeability / Q000187:drug effects / Q000502:physiology*; D002417:Cattle; D042783:Endothelial Cells / Q000166:cytology / Q000187:drug effects; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism*; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D016023:Integrins / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism*; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors; D008171:Lung Diseases / Q000139:chemically induced / Q000473:pathology; D051379:Mice; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D011651:Pulmonary Artery / Q000166:cytology / Q000187:drug effects; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D019030:Receptors, Vitronectin / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism*; D015427:Reperfusion Injury; D022502:Stress Fibers / Q000187:drug effects; D012122:Ventilators, Mechanical; D054460:rho-Associated Kinases
D000577:Amides; D000906:Antibodies; D016023:Integrins; D047908:Intracellular Signaling Peptides and Proteins; D011725:Pyridines; D019030:Receptors, Vitronectin; C064660:integrin alphaVbeta5; C108830:Y 27632; D017346:Protein Serine-Threonine Kinases; D054460:rho-Associated Kinases